版本:
中国

BRIEF-Revance Therapeutics updates on phase 2 clinical trial results

June 15 Revance Therapeutics Inc:

* Positive Belmont phase 2 trial results published in dermatologic surgery

* All dose levels of RT002 appeared to be generally safe and well-tolerated

* When compared to placebo, all dose levels of RT002 achieved highly statistically significant efficacy at week 4 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐